Zoetis (ZTS) Given a $85.00 Price Target at Cantor Fitzgerald

Zoetis (NYSE:ZTS) has been given a $85.00 price target by Cantor Fitzgerald in a research note issued on Tuesday. The firm presently has a “buy” rating on the stock. Cantor Fitzgerald’s target price would indicate a potential upside of 17.50% from the stock’s previous close.

A number of other equities analysts have also recently issued reports on the stock. Morgan Stanley raised shares of Zoetis from an “equal weight” rating to an “overweight” rating and set a $80.00 target price on the stock in a report on Wednesday, November 29th. UBS Group reissued a “neutral” rating on shares of Zoetis in a report on Friday, November 24th. Cowen set a $80.00 target price on shares of Zoetis and gave the stock a “buy” rating in a report on Friday, November 17th. Jefferies Group reissued a “buy” rating on shares of Zoetis in a report on Friday, November 10th. Finally, BidaskClub raised shares of Zoetis from a “hold” rating to a “buy” rating in a report on Tuesday, November 7th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and thirteen have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $68.82.

Zoetis (NYSE ZTS) opened at $72.34 on Tuesday. The company has a quick ratio of 1.95, a current ratio of 2.80 and a debt-to-equity ratio of 2.45. Zoetis has a twelve month low of $52.00 and a twelve month high of $73.58. The stock has a market cap of $35,070.00, a PE ratio of 38.07, a price-to-earnings-growth ratio of 2.16 and a beta of 1.06.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, November 2nd. The company reported $0.65 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.63 by $0.02. Zoetis had a net margin of 18.29% and a return on equity of 62.39%. The firm had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $1.32 billion. During the same quarter last year, the company posted $0.52 earnings per share. Zoetis’s revenue was up 8.5% on a year-over-year basis. equities analysts expect that Zoetis will post 2.37 EPS for the current fiscal year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Northwestern Mutual Wealth Management Co. raised its holdings in shares of Zoetis by 16.8% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 1,598 shares of the company’s stock valued at $100,000 after buying an additional 230 shares during the last quarter. Steward Partners Investment Advisory LLC acquired a new position in shares of Zoetis during the third quarter valued at approximately $114,000. Harfst & Associates Inc. increased its stake in shares of Zoetis by 16.1% during the second quarter. Harfst & Associates Inc. now owns 1,878 shares of the company’s stock valued at $117,000 after acquiring an additional 260 shares during the period. Almanack Investment Partners LLC. acquired a new position in shares of Zoetis during the second quarter valued at approximately $119,000. Finally, Mitsubishi UFJ Securities Holdings Co. Ltd. increased its stake in shares of Zoetis by 251.9% during the third quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,900 shares of the company’s stock valued at $121,000 after acquiring an additional 1,360 shares during the period. 93.19% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Zoetis (ZTS) Given a $85.00 Price Target at Cantor Fitzgerald” was first published by Community Financial News and is owned by of Community Financial News. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.com-unik.info/2017/12/27/zoetis-zts-given-a-85-00-price-target-at-cantor-fitzgerald.html.

Zoetis Company Profile

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Analyst Recommendations for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit